▶주메뉴 바로가기
▶본문 바로가기
[ THE INVESTOR ] Celltrion shares climbed 4.55 percent on May 8 as sales of its biosimilar Inflectra showed strong growth in the US. Stocks of the Korean biopharmaceutical firm were trading at 94...
[ THE INVESTOR ] The first-quarter earnings of Pfizer and US-based Merck & Co. appear to have been affected by sales of Celltrion’s Remsima, a biosimilar copy of Johnson & Johnson’s Remicade. Pf...
[ THE INVESTOR ] South Korean biopharma company Celltrion , whose biosimilar copy of Johnson & Johnson’s Remicade hit the US market last year, is planning to seek regulatory approval for two add...
[ THE INVESTOR ] Yungjin Pharmaceutical said on May 2 it has reached an exclusive licensing agreement with Swedish drug maker NeuroVive Pharmaceutical to develop its experimental compound for gener...
[ THE INVESTOR ] Shares of Samsung BioLogics rose 21.85 percent this year, becoming the biggest gainer among the large cap stocks on Korea’s main bourse KOSPI, according to Korea Exchange on May...
[ THE INVESTOR ] Korean botulinum toxin maker Hugel , which will be acquired by Bain Capital, has posted its highest operating profit on record in the first quarter, driven by strong exports of ...
[ THE INVESTOR ] The Korean unit of Swiss drug giant Novartis was slapped with a 55.1 billion won (US$48.80 million) fine and insurance coverage suspensions for giving illegal kickbacks to doctors ...
[ THE INVESTOR ] Celltrion Healthcare, the sales and marketing unit of Korean drug maker Celltrion , said on April 27 it has named Nippon Kayaku as its Japanese retail partner for Truxima. The J...
[ THE INVESTOR ] Korea’s Celltrion said April 26 that it has won all of its patent infringement suits involving Roche’s blockbuster breast cancer drug Herceptin in Korea, paving the way for the l...
[ THE INVESTOR ] Korean biotech firm Alteogen said April 26 has signed a letter of intent to license its long-acting drug for growth hormone deficiency with Brazil’s Cristalia for its developmen...
[ THE INVESTOR ] US pharmaceutical giant Pfizer said on April 26 it has promoted five executives at the Korean unit to manage positions in the Asia-Pacific region. Pfizer Korea Vice President Kim ...
[ THE INVESTOR ] Celltrion and its retail partner Pfizer plan to complete switching studies of the Korean drug maker’s biosimilar Inflectra, known as Remsima in Europe, to demonstrate its interch...
[ THE INVESTOR ] Korean biotech company Panagene plans to apply for regulatory approval of its own liquid biopsy testing in the US this year with aims to compete head-on with its bigger rival Roc...
[ THE INVESTOR ] South Korea’s Samsung Bioepis won the US Food and Drug Administration’s approval for its biosimilar copy of Johnson & Johnson’s Remicade on April 22, becoming a new challenger to ...
[ THE INVESTOR ] Alteogen is accelerating the development of a biosimilar version of the world’s top breast cancer drug Herceptin to join two other Korean firms in challenging big pharma Roche. ...
This week's DECODED X
Samsung's share in Chinese smartphone market falls to 3%
Celltrion’s earnings double on strong Remsima sales
SK hynix increases facility investment to W10tr
Hyundai Kona sales to exceed 10,000 units in July
Renault likely to produce Twizy in Korea
Samsung Bioepis heats up price war in Remicade biosimilar market
SK to invest W372b in Chinese logistics firm
